pac-1 Antibody

What is PAC-1 antibody and what epitope does it recognize?

PAC-1 is a mouse monoclonal antibody (IgM, kappa) that recognizes an activation-induced conformational epitope on the CD41/CD61 complex (gpIIb/IIIa), also known as integrin alpha IIb beta 3, a receptor that mediates platelet aggregation . Unlike antibodies that bind to the receptor regardless of its activation state, PAC-1 specifically binds to activated platelets but not to resting cells . This makes it particularly useful for studying platelet activation.

The specificity of PAC-1 for activated αIIbβ3 is determined by an integrin recognition sequence within its heavy chain complementarity-determining region 3 (H-CDR3), which contains an Arg-Tyr-Asp sequence . This sequence is essential for PAC-1's ability to recognize activated αIIbβ3, and mutation of the Asp residue to Glu renders the antibody inactive . The epitope recognized by PAC-1 is extracellular and activation-dependent, meaning it's only exposed following platelet activation .

How does PAC-1 antibody differ from PSMG1/PAC1 protein?

It's important to clarify that there are different entities with similar names that should not be confused:

• PAC-1 antibody: A mouse monoclonal antibody that recognizes activated integrin αIIbβ3 on platelets .

• PSMG1/PAC1 protein: Proteasome assembly chaperone 1, an evolutionarily conserved, ubiquitously expressed chaperone protein that promotes proper biogenesis of the α-ring of the 20S CP of the eukaryotic proteasome . This protein functions in a heterodimeric complex with PSMG2 (PAC2) and was originally identified as a proteasome subunit binding partner .

• PAC 1 antigens: In a different context, PAC 1 refers to epitopes associated with two postsynaptic density-enriched glycoproteins and a cytoskeleton-enriched polypeptide found in the developing rat forebrain .

These are entirely distinct entities with different structures, functions, and applications in research, despite the similar nomenclature.

What are the common applications of PAC-1 antibody in research?

PAC-1 antibody has several important research applications:

• Flow Cytometry: The primary application is analyzing platelet activation status in human blood samples. Typical protocols use 4 μl reagent per 100 μl of whole blood or 10^6 cells in suspension . This application allows researchers to quantify the proportion of activated platelets in various physiological and pathological states.

• Western Blotting (WB): For detecting PAC-1 protein in cell or tissue lysates .

• Immunoprecipitation (IP): For isolating PAC-1 protein from complex mixtures .

• Immunofluorescence (IF): For visualizing the localization of PAC-1 in cells or tissues .

• Immunohistochemistry with paraffin-embedded sections (IHCP): For detecting PAC-1 in tissue sections .

The antibody is available in various conjugated forms, including FITC, PE, and other fluorescent conjugates for flow cytometry applications, as well as HRP conjugates for Western blotting and immunohistochemistry . These various formats provide flexibility for different experimental designs.

How does PAC-1 antibody binding relate to platelet activation?

PAC-1 antibody binding to platelets is directly related to platelet activation status. In resting platelets, the integrin αIIbβ3 is in a low-affinity conformation that does not bind PAC-1 . Upon platelet activation by agonists such as thrombin, ADP, or collagen, intracellular signaling leads to a conformational change in αIIbβ3 (inside-out signaling), exposing binding sites for fibrinogen and other ligands.

PAC-1 antibody recognizes this activated conformation, making it a valuable tool for detecting platelet activation . The binding of PAC-1 to activated platelets can be inhibited by 10 mM EDTA, 1 mM RGDS, 1 mM fibrinogen gamma 397-411, or 12 μM fibrinogen, but not by 1 mM RGES . This inhibition pattern indicates that PAC-1 binds to or near the ligand-binding site of activated αIIbβ3.

Interestingly, while fibrinogen or PAC-1 IgM binding to platelets can induce tyrosine phosphorylation of a 140-kDa platelet protein (outside-in signaling), the monovalent PAC-1 Fab fragment does not induce this phosphorylation . This suggests that antibody valency affects its signaling properties, with multivalent binding necessary for triggering outside-in signaling.

How can I optimize PAC-1 antibody for flow cytometry experiments?

To optimize PAC-1 antibody for flow cytometry experiments, consider the following methodological approaches:

What is the molecular mechanism behind PAC-1 antibody's specificity?

The molecular mechanism behind PAC-1 antibody's specificity for activated platelets involves several key factors:

• Recognition sequence: PAC-1 contains an Arg-Tyr-Asp (RYD) sequence at residues 100A-C in H-CDR3 . This sequence mimics the Arg-Gly-Asp (RGD) motif found in fibrinogen and other αIIbβ3 ligands. The RYD sequence is essential for PAC-1's specificity, as demonstrated by the fact that converting Asp100C to Glu renders the antibody inactive .

• Conformational epitope recognition: PAC-1 binds to a conformational epitope that is exposed only when αIIbβ3 undergoes activation-induced conformational changes . These changes involve the extension of the integrin from a bent to an extended conformation.

• Binding site: PAC-1 likely binds at or near the ligand-binding pocket of αIIbβ3, as evidenced by the ability of RGDS peptides, fibrinogen gamma 397-411, and fibrinogen itself to competitively inhibit PAC-1 binding .

• Dependence on divalent cations: PAC-1 binding is inhibited by EDTA, indicating a requirement for divalent cations (likely calcium) for proper integrin conformation and/or antibody binding .

• Specificity for αIIbβ3: PAC-1 binds specifically to activated αIIbβ3 and does not bind to resting αIIbβ3 or to other integrins like αvβ3, despite structural similarities . This specificity has been confirmed in Chinese hamster ovary cells expressing activated αIIbβ3.

How does the valency of PAC-1 antibody affect its binding and signaling?

The valency of PAC-1 antibody significantly affects both its binding avidity and signaling properties:

• Binding avidity:

  • PAC-1 IgM: As an IgM antibody, PAC-1 has multiple antigen-binding sites, providing high avidity through multivalent binding to activated αIIbβ3 .

  • PAC-1 Fab: The monovalent Fab fragment has only one binding site, resulting in lower avidity. Studies show that a 60-fold higher molar concentration of PAC-1 Fab is required for half-maximal binding to platelets compared to PAC-1 IgM .

• Signaling properties:

  • PAC-1 IgM: Binding of the multivalent PAC-1 IgM to platelets induces tyrosine phosphorylation of a 140-kDa platelet protein, similar to fibrinogen binding . This suggests that multivalent binding can trigger outside-in signaling through αIIbβ3.

  • PAC-1 Fab: In contrast, binding of the monovalent PAC-1 Fab does not induce tyrosine phosphorylation . This indicates it cannot trigger the same signaling events, suggesting that receptor clustering, which requires multivalent binding, is necessary for outside-in signaling.

• Functional implications:

  • PAC-1 IgM may not only detect activated αIIbβ3 but also modulate platelet function by triggering downstream signaling pathways.

  • The monovalent Fab is more suitable for detecting activated αIIbβ3 without altering platelet function, making it a better choice when minimal perturbation is desired.

What controls should be included when using PAC-1 antibody?

For rigorous research with PAC-1 antibody, the following controls are essential:

• Isotype control: Mouse IgM (kappa) conjugated to the same fluorochrome as the PAC-1 antibody (e.g., FITC) to establish background fluorescence and non-specific binding .

• Negative biological controls:

  • Resting platelets (unstimulated) should show minimal binding of PAC-1 .

  • Samples treated with 10 mM EDTA, which chelates calcium and prevents αIIbβ3 activation .

  • Samples pre-incubated with competitive inhibitors like 1 mM RGDS peptide or 1 mM fibrinogen gamma 397-411, which should block PAC-1 binding to activated platelets .

• Positive biological controls:

  • Platelets activated with known agonists to demonstrate maximum PAC-1 binding.

  • Different agonist concentrations to create a dose-response curve for platelet activation.

• Specificity controls:

  • 1 mM RGES peptide as a negative control for RGDS inhibition, as it doesn't inhibit PAC-1 binding .

  • Comparison with other activation markers to confirm platelet activation status.

• Technical controls:

  • Single-stained samples for compensation when performing multicolor flow cytometry.

  • Unstained samples to establish autofluorescence levels.

These controls help validate the specificity of PAC-1 binding and ensure accurate interpretation of results in both basic and advanced research applications.

How can I use PAC-1 antibody to study platelet dysfunction in clinical samples?

PAC-1 antibody provides valuable insights into platelet dysfunction in clinical samples through several methodological approaches:

• Baseline activation assessment:

  • Flow cytometric analysis of PAC-1 binding to platelets from patients compared to healthy controls can reveal abnormal baseline activation.

  • This approach can identify hyperreactive platelets in various thrombotic disorders or hypoactive platelets in bleeding disorders.

• Platelet reactivity testing:

  • Measure PAC-1 binding in response to increasing concentrations of agonists (ADP, collagen, thrombin) to assess platelet reactivity.

  • Increased sensitivity to agonists (left-shifted dose-response curve) may indicate prothrombotic phenotypes.

  • Decreased responsiveness may indicate platelet dysfunction or effects of antiplatelet therapy.

• Dual-marker analysis:

  • Combine PAC-1 with other activation markers to distinguish between different aspects of platelet activation.

  • Different patterns of marker expression may characterize specific pathological conditions.

• Pharmacological studies:

  • Monitor the effects of antiplatelet drugs on PAC-1 binding to assess drug efficacy.

  • Identify patients with resistance to antiplatelet therapy through persistent PAC-1 binding despite treatment.

• Time-course studies:

  • Monitor changes in PAC-1 binding over time in patients experiencing acute events or following interventions.

  • This approach helps understand the dynamics of platelet activation in relation to clinical outcomes.

Methodological considerations include standardized blood collection and processing protocols to minimize pre-analytical variables and including appropriate controls to account for potential in vitro activation during sample handling .

How can I distinguish between different conformational states of αIIbβ3?

Distinguishing between different conformational states of integrin αIIbβ3 requires a strategic approach using multiple antibodies, including PAC-1:

• Conformational states of αIIbβ3:

  • Bent-closed (resting): Low-affinity state, predominant on resting platelets

  • Extended-open: High-affinity state, capable of binding soluble ligands, recognized by PAC-1

• Antibody panel for comprehensive analysis:

  a. PAC-1:

  • Recognizes the high-affinity conformation of αIIbβ3

  • Binds to or near the ligand-binding site

  • Binding requires activation-induced conformational changes

  b. Anti-LIBS (Ligand-Induced Binding Site) antibodies:

  • Recognize epitopes exposed only after ligand binding

  • Can distinguish ligand-occupied αIIbβ3 from activated but unoccupied αIIbβ3

  c. Conformation-insensitive antibodies:

  • Bind to epitopes that are accessible regardless of activation state

  • Useful for normalizing to total αIIbβ3 expression

• Experimental approaches:

  a. Sequential antibody binding:

  • First bind PAC-1 to detect activated αIIbβ3

  • Then add fibrinogen or other ligands

  • Finally add LIBS antibodies to detect ligand-bound receptors

  b. Competitive binding assays:

  • Compare binding of PAC-1 versus natural ligands (fibrinogen)

  • Assess competitive inhibition patterns

  • Different conformational states may show different competition profiles

  c. Cation manipulation:

  • Use EDTA to lock integrins in inactive conformation

  • Compare PAC-1 binding under different conditions

• Data interpretation framework:

  • PAC-1-positive platelets represent cells with activated αIIbβ3

  • The intensity of PAC-1 binding correlates with the extent of integrin activation

  • Correlation with functional assays provides validation of the conformational state assessment

What are the optimal storage conditions for PAC-1 antibody?

Based on the product information provided in the search results, PAC-1 antibody should be stored according to these specific conditions:

• Temperature: Store at 2-8°C (refrigerated)

• Light exposure: Keep in the dark, especially for fluorochrome-conjugated versions

• Critical note: DO NOT FREEZE the antibody

The antibody is typically supplied in a buffer containing:

• Tris Buffered Saline (TBS), pH 8

• 0.2% BSA

• 15 mM sodium azide as a preservative

Proper storage is crucial to maintain the antibody's specificity and activity. Avoid repeated freeze-thaw cycles, which can lead to antibody degradation and loss of function. Following these storage recommendations will ensure optimal performance in experimental applications.

What are the recommended dilutions for different applications?

Based on the search results, the following dilutions and applications are recommended for PAC-1 antibody:

These recommended dilutions provide starting points for optimization in your specific experimental system. Optimal dilutions may vary depending on cell type, sample preparation, detection method, and the specific conjugate being used. For applications not specifically mentioned in the search results, it's advisable to perform a titration experiment to determine the optimal concentration for your particular application.

How does PAC-1 differ from other platelet activation markers?

PAC-1 has several distinctive characteristics compared to other common platelet activation markers:

• Target recognition:

  • PAC-1 specifically recognizes the activated conformation of integrin αIIbβ3

  • In contrast, anti-P-selectin (CD62P) antibodies detect alpha-granule release, while anti-CD63 antibodies detect dense granule release

• Temporal dynamics:

  • αIIbβ3 activation (detected by PAC-1) occurs rapidly after platelet stimulation

  • Granule release (detected by anti-P-selectin) may have different kinetics

• Signaling pathway specificity:

  • Different activation markers may respond differently to various agonists or inhibitors

  • This allows researchers to dissect specific signaling pathways involved in platelet activation

• Functional relevance:

  • PAC-1 binding directly correlates with the platelet's ability to bind fibrinogen and aggregate

  • Other markers may indicate activation but not necessarily aggregation potential

• Sensitivity to inhibitors:

  • PAC-1 binding is inhibited by EDTA, RGDS peptides, and fibrinogen

  • Other markers may be differentially affected by these inhibitors

• Antibody characteristics:

  • PAC-1 is an IgM antibody with multivalent binding properties

  • Many other activation markers are detected using IgG antibodies with different binding properties

Understanding these differences allows researchers to select the most appropriate markers for specific research questions and to interpret their results in the context of the platelet activation pathways being studied.

Future directions in PAC-1 antibody research

The PAC-1 antibody continues to be an important tool in platelet research, with several promising future directions:

• Development of improved variants:

  • Creation of recombinant versions with defined properties

  • Engineering antibodies with modified RYD sequences to further enhance specificity

  • Development of smaller fragments or mimetics that retain activation-specific binding

• Clinical applications:

  • Standardization of PAC-1 flow cytometry protocols for clinical testing

  • Development of point-of-care tests based on PAC-1 recognition of activated platelets

  • Use of PAC-1 binding as a biomarker for risk stratification in thrombotic disorders

• Advanced microscopy applications:

  • Utilization of PAC-1 in super-resolution microscopy to study integrin clustering

  • Real-time imaging of integrin activation dynamics using PAC-1 derivatives

  • Correlation of PAC-1 binding with structural changes in platelets

• Mechanistic studies:

  • Further elucidation of the precise epitope recognized by PAC-1

  • Investigation of how different activation pathways affect the PAC-1 binding site

  • Comparative studies of PAC-1 binding to integrins from different species

• Drug development:

  • Use of PAC-1's unique binding properties as a template for therapeutic agents

  • Development of PAC-1-like molecules that can selectively target activated integrins

  • Screening platforms using PAC-1 competition to identify novel antiplatelet agents

These future directions highlight the continuing relevance of PAC-1 antibody in both basic research and translational applications, building on its well-established role in platelet biology and thrombosis research.